BACKGROUND: Some drugs that target molecular pathways are available for the targeted treatment of lung cancer. Multiple tests are needed to detect the status of the known molecular targets to determine whether the patients can respond to the drugs. An integrated platform for various gene alteration detection including both mutations and rearrangements is necessary for patients, especially those without enough tissue. METHODS: In our study, detections of EGFR mutations, ALK rearrangement, ROS1 rearrangement, and alterations of other nine important lung cancer-related genes were integrated into a single next-generation sequencing (NGS) platform. The NGS analysis was performed in 107 cases of non-small cell lung cancer (NSCLC). Meanwhile, hot spots such as EGFR L858R, EGFR E746-A750Del mutations and gene rearrangement of ALK and ROS1 were detected by immunohistochemical (IHC) staining. RESULTS: NGS could explore various gene mutations and gene rearrangements with a reduced experiment time and lower amounts of tumor tissues than multiple IHC staining experiments. NGS results were more informative and reliable than IHC staining for EGFR gene alterations, especially for the exon 19 region. NGS could also increase the positive rate of ALK rearrangement and decrease the false positive results of ROS1 rearrangements detected by IHC staining. CONCLUSIONS: NGS is effective for confirmation the status of various important lung cancer-related gene alterations. Furthermore, NGS is necessary for the confirmation of the IHC results of ALK and ROS1 rearrangements. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Some drugs that target molecular pathways are available for the targeted treatment of lung cancer. Multiple tests are needed to detect the status of the known molecular targets to determine whether the patients can respond to the drugs. An integrated platform for various gene alteration detection including both mutations and rearrangements is necessary for patients, especially those without enough tissue. METHODS: In our study, detections of EGFR mutations, ALK rearrangement, ROS1 rearrangement, and alterations of other nine important lung cancer-related genes were integrated into a single next-generation sequencing (NGS) platform. The NGS analysis was performed in 107 cases of non-small cell lung cancer (NSCLC). Meanwhile, hot spots such as EGFR L858R, EGFR E746-A750Del mutations and gene rearrangement of ALK and ROS1 were detected by immunohistochemical (IHC) staining. RESULTS: NGS could explore various gene mutations and gene rearrangements with a reduced experiment time and lower amounts of tumor tissues than multiple IHC staining experiments. NGS results were more informative and reliable than IHC staining for EGFR gene alterations, especially for the exon 19 region. NGS could also increase the positive rate of ALK rearrangement and decrease the false positive results of ROS1 rearrangements detected by IHC staining. CONCLUSIONS: NGS is effective for confirmation the status of various important lung cancer-related gene alterations. Furthermore, NGS is necessary for the confirmation of the IHC results of ALK and ROS1 rearrangements. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate Journal: N Engl J Med Date: 2014-09-27 Impact factor: 91.245
Authors: William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus Journal: Proc Natl Acad Sci U S A Date: 2004-08-25 Impact factor: 11.205
Authors: Ming-Tseh Lin; Stacy L Mosier; Michele Thiess; Katie F Beierl; Marija Debeljak; Li-Hui Tseng; Guoli Chen; Srinivasan Yegnasubramanian; Hao Ho; Leslie Cope; Sarah J Wheelan; Christopher D Gocke; James R Eshleman Journal: Am J Clin Pathol Date: 2014-06 Impact factor: 2.493
Authors: Gillian Ellison; Emma Donald; Gael McWalter; Lucy Knight; Lynn Fletcher; James Sherwood; Mireille Cantarini; Maria Orr; Georgina Speake Journal: J Exp Clin Cancer Res Date: 2010-10-06
Authors: Richard S P Huang; Amanda Gottberg-Williams; Panhia Vang; Shoua Yang; Nicholas Britt; Jaspreet Kaur; James Haberberger; Natalie Danziger; Clarence Owens; Sara E Beckloff; Jeffrey S Ross; Shakti H Ramkissoon Journal: JTO Clin Res Rep Date: 2020-09-18
Authors: Yoon Ji Choi; Jung Yoon Choi; Ju Won Kim; Ah Reum Lim; Youngwoo Lee; Won Jin Chang; Soohyeon Lee; Jae Sook Sung; Hee-Joon Chung; Jong Won Lee; Eun Joo Kang; Jung Sun Kim; Taekyu Lim; Hye Sook Kim; Yu Jung Kim; Mi Sun Ahn; Young Saing Kim; Ji Hyun Park; Seungtaek Lim; Sung Shim Cho; Jang Ho Cho; Sang Won Shin; Kyong Hwa Park; Yeul Hong Kim Journal: Cancer Res Treat Date: 2021-05-20 Impact factor: 4.679